SGLT2 inhibitors can be used for the secondary prevention of cardiovascular outcomes in patients with T2DM and a history of cardiovascular disease in consideration of their beneficial cardiovascular and metabolic effects. The gene discussed is SLC5A2; the disease is cardiovascular disorder.